● AI Equity Research · Healthcare

Align Technology, Inc. (ALGN)

AI stock analysis · Medical Instruments & Supplies · Last analyzed Aug 17, 2026

Compass Score

3.0/5

Call

Hold

Price

$181.31

AI Target

$208.60 +15.1%

AI Analyst Summary

Align Technology offers a compelling forward valuation re-rating story, with the forward P/E compressing to 14.4x and a sub-1.0 PEG of 0.86 — both signaling the market may be underpricing a potential earnings recovery in the clear aligner and intraoral scanner markets. A perfect 4-of-4 recent EPS beat rate and a solid Buy consensus from 15 analysts reinforce near-term execution credibility. The primary risk is the -12.1% YoY earnings decline, which must reverse for the bullish thesis to materialize.

Catalysts

Earnings recovery inflection in upcoming quarters — the gap between trailing P/E (31.4x) and forward P/E (14.4x) implies consensus expects a significant EPS rebound, making the next 1–2 quarterly reports pivotal confirmation events.
Potential volume acceleration in the Invisalign clear aligner segment driven by orthodontic practice expansion and consumer demand recovery in key international markets, particularly APAC and EMEA.
Continued adoption of iTero intraoral scanners as a digital workflow integrator, with scanner attach rates and recurring software/services revenue acting as a high-margin growth lever.

Fundamentals

Pe Trailing P/E 31.4x / Forward P/E 14.4x · 4.0/5

Trailing P/E of 31.4x appears elevated but the forward P/E of 14.4x is materially below the healthcare sector median, suggesting earnings are expected to recover sharply. The compression from trailing to forward is a constructive signal.

Peg PEG 0.86 · 5.0/5

PEG below 1.0 is a strong value signal relative to growth expectations. At 0.86, the stock appears undervalued relative to its long-term earnings growth trajectory, supporting a bullish setup.

Analyst Rating Buy consensus (2.0) · 4.0/5

Consensus of 2.0 reflects a solid Buy rating from 15 analysts (10 Buy / 6 Hold / 1 Sell). Broad analyst coverage with a strong bullish tilt provides meaningful conviction in the setup.

Earnings Trend EPS Growth YoY: -12.1% | Revenue Growth YoY: +4.3% · 2.0/5

YoY earnings growth of -12.1% is a clear headwind and the primary concern. Revenue growth of 4.3% is modest but positive, suggesting the top line is intact while margin or cost pressures are compressing the bottom line. The sharp drop in forward P/E implies consensus expects a meaningful earnings rebound.

Price Target Beat 4 of 4 quarters beat (last 4 quarters) · 3.0/5

A perfect 4-for-4 EPS beat rate over the last 4 quarters is encouraging and shows consistent execution against expectations. However, with only 4 quarters of data, the score is capped at 3 per guidelines — insufficient full 8-quarter history to award higher.

Management Consistent EPS beater with bullish analyst support · 4.0/5

A 100% EPS beat rate over the available 4-quarter window, combined with strong analyst conviction (10 of 15 analysts at Buy), suggests management is effectively guiding expectations and executing against them. Slight discount applied due to the earnings growth decline requiring further monitoring.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.